Harness Dickey, one of the country’s premier intellectual property law firms, is pleased to congratulate firm client Pear Therapeutics on the recent FDA approval of their innovative prescription digital therapeutic application. This marks the first time that the FDA has approved a mobile app to treat Substance Use Disorder, or SUD.
“With this recent approval from the FDA, we are able to set a clear course for our innovative technology to improve the lives of patients being treated for SUD,” said Corey McCann, Founder and CEO of Pear Therapeutics. “It’s an exciting time for digital therapeutics and we are eager to grow our product line and software IP to improve patient outcomes across a range of conditions.”
The FDA approved mobile app developed by Pear Therapeutics, known as reSET®, is prescribed by a clinician as part of a treatment program that also includes face to face counseling. The company offers reSET® and other digital therapeutic products designed to provide improved patient outcomes, better tracking for clinicians and cost-effective solutions for patients.
The digital therapeutics space is a relatively new medical field in which software modules, including mobile apps and desktop applications, are used to treat a range of conditions. As a newer field, there is increasing competition from universities, large biopharma corporations and start-up companies. “With the field heating up, we are working hard to protect Pear Therapeutics’ new intellectual property and strategically grow their patent portfolio,” said Scott Barnett, Attorney with Harness Dickey and counsel to Pear Therapeutics. “This will lay a solid foundation for the company’s growth, while solidifying its position as the lead innovator in this burgeoning field.”
Pear Therapeutics is currently awaiting approval of their reSET-O® application developed specifically to treat patients addicted to opioids. Promisingly, a recent FDA announcement named Pear Therapeutics to a list of nine companies — chosen from more than one hundred applicants — who will participate in a new pre-certification program that could benefit patients-in-need by providing a fast-track to market for Pear’s innovative digital therapeutic product line.
About Pear Therapeutics
Pear Therapeutics is the leader in FDA-cleared Prescription Digital Therapeutics. The company integrates clinically-validated software applications with previously approved pharmaceuticals and treatment paradigms to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear’s lead product, reSET®, is an FDA-cleared 12-week interval prescription therapy for Substance Use Disorder (SUD) to be used as an adjunct to standard, outpatient treatment. Pear’s product development pipeline includes reSET-O™ for opioid use disorder (OUD) and additional prescription digital therapeutics in schizophrenia (Thrive™), combat post-traumatic stress disorder (reCALL™), general anxiety disorder (reVIVE™), pain, major depressive disorder, and insomnia. For more details, please see www.peartherapeutics.com.
About Harness Dickey
Harness Dickey was founded in 1921 and is currently ranked seventh among the nation’s top patent firms in a 2016 poll by IPWatchdog. Harness Dickey safeguards critical IP assets on a global scale for Fortune 500 companies, private and public businesses, universities, inventors, artists and entrepreneurs. Harness Dickey has offices in the metropolitan areas of Dallas, Detroit, St. Louis and Washington, D.C. Visit www.hdp.com and follow @harnessdickey for more information.